New antifungal strategies and drug development against WHO critical priority fungal pathogens
Frontiers in Cellular and Infection Microbiology · 25.09.2025 · 15
DOI: 10.3389/fcimb.2025.1662442 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 25.09.2025. Verfasst von Yanjian Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Life and Health Sciences, Northeastern University, Shenyang, China. Hauptthemen laut MEDLINE: Antifungal Agents, Drug Development, Mycoses, Fungi. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 492 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fungal infections pose a significant threat to human health, particularly in immunocompromised individuals, driving a sustained increase in the demand for effective antifungal agents. These agents can be classified into several categories based on their mechanisms of action and chemical structures, including inhibitors of sterol synthesis, cell wall synthesis, DNA synthesis, and cell membrane function. Each class exerts its antifungal effects through distinct molecular pathways that disrupt fungal cell growth and reproduction. However, the clinical utility of current antifungal therapies is hindered by challenges such as the emergence of drug resistance, limited antifungal spectra, and adverse side effects. Consequently, the development of safe and efficacious antifungal agents remains a pressing need. This review provides a comprehensive overview of the classification and molecular mechanisms of antifungal drugs, discusses the current challenges in antifungal therapy, and explores potential strategies for future drug development, aiming to inform and advance antifungal research and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life and Health Sciences, Northeastern University, Shenyang, China.
- School of Life Science and Bio-pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
Zitieren
APA
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025). New antifungal strategies and drug development against WHO critical priority fungal pathogens. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1662442
Vancouver
Li Y, Liu Y, Jiang Y, Yang Y, Ni W, Zhang W, et al. New antifungal strategies and drug development against WHO critical priority fungal pathogens. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1662442
BibTeX
@article{Li2025,
author = {Li, Yanjian and Liu, Yang and Jiang, Yicong and Yang, Yusen and Ni, Wanxing and Zhang, Wanli and Tan, Lingchen},
title = {New antifungal strategies and drug development against WHO critical priority fungal pathogens},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1662442}
}
EUVIMED